Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005151 | 0.94 | CA12 (0.38) | CA12CA2CA9TSHRALDH1A1 | |
| SCHEMBL14005163 | 0.94 | CA12 (0.38) | CA12CA2CA9TSHRALDH1A1 | |
| SCHEMBL22098728 | 0.92 | MEN1 (0.42) | CA12CA2CA9TSHRALDH1A1 | |
| SCHEMBL6899761 | 0.86 | CA12 (0.44) | CA12CA2CA9TSHRALDH1A1 | |
| SCHEMBL14388860 | 0.85 | CA12 (0.40) | CA12CA2CA9TSHRALDH1A1 | |
| SCHEMBL24092261 | 0.85 | MEN1 (0.37) | CA12CA2CA9TSHRALDH1A1 | |
| SCHEMBL14005179 | 0.85 | DGKA (0.33) | CA12CA2CA9TSHRALDH1A1 | |
| SCHEMBL8909554 | 0.83 | ALDH1A1 (0.52) | CA12CA2CA9TSHRALDH1A1 | |
| SCHEMBL14759196 | 0.81 | NAAA (0.50) | CA12CA2CA9TSHRALDH1A1 | |
| SCHEMBL14005175 | 0.80 | CHRNB2 (0.38) | CA12CA2CA9TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293660-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
| US-7351855-B2 | Chemically defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070254851-A1 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293660-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | SSB, PCNA, NCL | CA12 345/4885CA2 2390/4885CA9 1539/4885 |
| US-20070254851-A1 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | SSB, PCNA, NCL | CA12 345/4885CA2 2390/4885CA9 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.